ILIT.FT Dose finding for intralymphatic allergen immunotherapy in a randomized, parallel group, double blind placebo-controlled field trial
Latest Information Update: 28 Apr 2022
At a glance
- Drugs House dust mite allergy immunotherapy injection ALK Abello (Primary)
- Indications Allergic rhinitis; Rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms ILIT.FT
- 28 Apr 2022 Status changed from recruiting to completed.
- 28 Jun 2021 New trial record